Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 9 - Medicinal preparations characterised by special physical form
Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
09/2003
09/04/2003WO2003071986A2 Method for treating otic disorders
09/04/2003WO2003071930A2 Systems and methods for remotely controlling medication infusion and analyte monitoring
09/04/2003WO2003071882A1 Method of colouring dragees and the composition used
09/04/2003WO2003063840A3 Transmucosal delivery of proton pump inhibitors
09/04/2003WO2003045306A3 Phenoxy amine compounds and compositions for delivering active agents
09/04/2003WO2003044187A3 Emulsion compositions
09/04/2003WO2003043660A3 Composition for stabilizing hyaluronic acid
09/04/2003WO2003037304B1 Controlled release compositions for macrolide antimicrobial agents
09/04/2003WO2003024432A3 Device for transdermal administration for the treatment of urinary tract disorders
09/04/2003WO2003020265A3 Compositions comprising pectin and ascorbic acid
09/04/2003WO2003018743A3 Emu-based formulations for wound treatment
09/04/2003WO2003015760A8 Use of dmso in the treatment of neurodegenerative diseases caused by prions
09/04/2003WO2003005967A3 Dual release levodopa ethyl ester and decarboxylase in controlled release core
09/04/2003WO2002066014A3 Cubic liquid crystalline compositions and methods for their preparation
09/04/2003WO2002064062A8 Vertebroplasty injection device and bone cement therefor
09/04/2003WO2002057436A3 Red blood cell from a transgenic animal as vehicle for polypeptide delivery
09/04/2003WO2002049501A3 Local regional chemotherapy and radiotherapy using in situ hydrogel
09/04/2003WO2002032943A9 Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization
09/04/2003US20030167261 Small-footprint applicative query interpreter method, system and program product
09/04/2003US20030167073 Transdermal or transmucosal drug delivery device
09/04/2003US20030167036 Flow condition sensor assembly for patient infusion device
09/04/2003US20030166990 Radiation delivery catheters and dosimetry methods
09/04/2003US20030166875 Fibroblast growth factor homologous factor-2 and methods of use
09/04/2003US20030166867 Fibrin nanoparticles and uses thereof
09/04/2003US20030166783 Bonding chitosan to polyoxyethylene glycol; gene therapy
09/04/2003US20030166763 Hard capsule filled with drug and polyethylene glycol
09/04/2003US20030166732 Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity
09/04/2003US20030166727 Antiinflammatory agents having analgesic, antianxiety, anticonvulsive, neuroprotective, antipsychotic and anticancer activity
09/04/2003US20030166722 4-hydroxy- alpha 1-(((6-(4-phenylbutoxy)-hexyl)-amino)-methyl)-1, 3-benzenedimethanol-4-phenylcinnamate salts for the tretment of asthma and chronic obstructive bronchitis
09/04/2003US20030166718 Dry powder granulated formulation of the compound racedotril useful for treating diarrhea
09/04/2003US20030166709 Use of an oily suspensions, containing the active ingredient in a solid phase a N-0923 (Rotigotine) for the treatment of diseases associated with dopamine metabolism, such as Parkinson's disease
09/04/2003US20030166705 Water-based liquid preparation
09/04/2003US20030166702 Contacting carvedilol and ethyl acetate to form a solution, and cooling the solution whereby a precipitate is formed; hypotensive agent
09/04/2003US20030166659 Administering a sustained release drug dosage-form including >5.0% by weight ranolazine in no more than two tablets per dose to maintain ranolazine plasma levels at a >850 ng base/mL for >24 hours; methacrylic acid copolymer binder
09/04/2003US20030166657 Treating an optically pure enantimer of zopiclone with 1-chloroethyl chloroformate or an azodicarboxylate followed hydrolysis; modulation of benzodiazepine receptors; sleep and behavioral disorders; anxiolytic agents
09/04/2003US20030166642 Administering synergistic mixtures of phenothiazine and pentamidine derivatives as anticarcinogenic agents
09/04/2003US20030166631 Pharmaceutical compositions and methods for administering EP2 receptor selective agonists
09/04/2003US20030166625 Penetration enhancing and irritation reducing systems
09/04/2003US20030166624 Sustained release mixtures of fluoxetine acetate or maleate, hydrocortisone, permeation intensifiers and cariers, applied to skin as topical antidepressants or for prophylaxis of obsessive compulsive disorder; drug delivery
09/04/2003US20030166611 Pharmaceutical carrier for external application thereof
09/04/2003US20030166608 Polysaccharide products from durian: process for isolation and purification and their applications
09/04/2003US20030166602 A delivery vehicle low molecular weight hyaluronan ligand, glycosaminoglycan ligand for binding to antigen, with antitumor agents, or anticancer agents
09/04/2003US20030166601 Drug delivery of the nucleic acid into a target tissue or cell, comprising a core complex contains a nucleic acid and complex forming agents, fusion with cell membranes with nuclear uptake; polymeric outer shell
09/04/2003US20030166592 For treatment of metabolic disorders (diabetes, obesity)
09/04/2003US20030166581 Coadministered with caffeine, for prevention of seizures; for treatment of Parkinson's/Alzheimer's disease; dietetics; smoking cessation
09/04/2003US20030166576 Urokinase inhibitors
09/04/2003US20030166553 Compositions for preventing and treating digestive organs diseases
09/04/2003US20030166537 Use of a gial cell line-derived growth factor (GDNF) or a functionally active derivative or part thereof and/or an agonist which substitutes the functional activity of GDNF, and/ or a nucleic acid containing at least a nucleotide
09/04/2003US20030166535 Preventing lesions of the upper alimentary canal, particularly oral aphthous or mucositis lesions. Intestinal trefoil peptides are administered in effective concentrations either alone or in combination with different therapeutic agents.
09/04/2003US20030166517 Galenical formulations
09/04/2003US20030166509 Pharmaceutical compositions comprising nanoparticles containing a sustained release bioactive agent, method of making such compositions, and method of therapy using such compositions.
09/04/2003US20030166508 Biologically active oral preparation that can be site-specific released in colon
09/04/2003US20030166487 Normally liquid, omega-hydrofluoroalkyl ether compounds (and selected mixtures thereof) have a saturated perfluoroaliphatic chain of carbon atoms interrupted by one or more ether oxygen atoms. The compounds can be prepared, by decarboxylation of
09/04/2003US20030166257 Use of Lactobacillus salivarius
09/04/2003US20030166057 Method and apparatus for the production of soluble MHC antigens and uses thereof
09/04/2003US20030165792 System for the controlled delivery of an active material to a dental site
09/04/2003US20030165572 Powder mixture containing starch; drying; anticholesterol agents
09/04/2003US20030165571 Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
09/04/2003US20030165570 Pharmaceutical compositions containing micronized bicyclic drugs
09/04/2003US20030165569 Composition for topical substance delivery
09/04/2003US20030165568 Stabilized steroidal suspension
09/04/2003US20030165567 Administering polypeptide by injection; gene therapy
09/04/2003US20030165566 Sedative non-benzodiazepine formulations
09/04/2003US20030165565 Diltiazem; controlled release; presleep administering; cardiovascular disorders
09/04/2003US20030165564 High speed releasing; storage stability
09/04/2003US20030165563 Dry blend tablet
09/04/2003US20030165562 Controlled release pharmaceutical composition
09/04/2003US20030165558 Antiallergic agent
09/04/2003US20030165555 Administering active polypeptide
09/04/2003US20030165551 Cosmetic and dermatological preparations based on O/W emulsions
09/04/2003US20030165545 Contact lenses; mixture of oil, water and surfactants
09/04/2003US20030165544 Injectable aqueous dispersions of propofol
09/04/2003US20030165512 Composition of antigen and glycolipid adjuvant for sublingual administration
09/04/2003US20030165478 Stabilized synthetic immunogen delivery system
09/04/2003US20030165438 Water-free ubichinon concentrate
09/04/2003US20030165437 Aerosos formulations containing P134a and particulate medicament
09/04/2003US20030165436 Formulations for use in inhaler devices
09/04/2003US20030165435 Using ethanol solvent
09/04/2003US20030164334 Method for obtaining a purified hydrofluoroalkane, purified hydrofluoroalkane, use of same and method for analysing same
09/04/2003US20030163931 Method for making homogeneous spray-dried soild amorphous drug dispersions utilizing modified spray-drying apparatus
09/04/2003CA2855045A1 Topical dapsone for the treatment of acne
09/04/2003CA2833470A1 Processes for preparing form 1 zd1839 polymorph
09/04/2003CA2776702A1 Topical dapsone for the treatment of acne
09/04/2003CA2702297A1 Novel crystalline forms of the anti-cancer compound zd1839
09/04/2003CA2662899A1 Pharmaceutical formulations of antineoplastic agents, in particular temozolomide, processes of making and using the same
09/04/2003CA2503094A1 Therapeutic methods for acute myeloid leukemia
09/04/2003CA2478475A1 Method for drying water-borne materials
09/04/2003CA2477350A1 Novel crystalline forms of the anti-cancer compound zd1839
09/04/2003CA2477105A1 Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity
09/04/2003CA2477049A1 Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride
09/04/2003CA2477044A1 Ophthalmic formulation with gum system
09/04/2003CA2476972A1 Pharmaceutical dosage form and method for the production thereof
09/04/2003CA2476769A1 Carbohydrate-modified polymers, compositions and uses related thereto
09/04/2003CA2476589A1 Compositions for delivery of therapeutics and other materials, and methods of making and using the same
09/04/2003CA2476171A1 Pharmaceutical dosage forms comprising tablet core having a tensile strength below 38 n/sqcm and a coating to protect the soft core
09/04/2003CA2476170A1 Fast disintegrating tablets
09/04/2003CA2475253A1 Therapeutical polyanhydride compounds for drug delivery
09/04/2003CA2473625A1 Oral trimethobenzamide formulations and methods
09/04/2003CA2473602A1 Oral pediatric trimethobenzamide formulations and methods
09/04/2003CA2473340A1 Formulations comprising a glp-1 compound and a delivery agent, and uses thereof
1 ... 2097 2098 2099 2100 2101 2102 2103 2104 2105 2106 2107 2108 2109 2110 2111 2112 2113 2114 2115 2116 2117 ... 2991